NASDAQ:AVEO - AVEO Pharmaceuticals Stock Price, Forecast & News

AVEO Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVEO."

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) announced its earnings results on Tuesday, November, 12th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.01 by $0.10. The biopharmaceutical company had revenue of $25.72 million for the quarter. AVEO Pharmaceuticals had a net margin of 120.85% and a negative return on equity of 561.43%. View AVEO Pharmaceuticals' Earnings History.

AVEO Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for AVEO Pharmaceuticals.

3 brokers have issued twelve-month target prices for AVEO Pharmaceuticals' stock. Their forecasts range from $1.75 to $2.00. On average, they expect AVEO Pharmaceuticals' share price to reach $1.88 in the next twelve months. This suggests a possible upside of 235.5% from the stock's current price. View Analyst Price Targets for AVEO Pharmaceuticals.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AVEO Pharmaceuticals in the last year. There are currently 1 sell rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AVEO Pharmaceuticals.

News coverage about AVEO stock has trended very negative this week, according to InfoTrie. The research group rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. AVEO Pharmaceuticals earned a daily sentiment score of -3.0 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for AVEO Pharmaceuticals.

AVEO Pharmaceuticals saw a decrease in short interest in January. As of January 31st, there was short interest totalling 16,400,000 shares, a decrease of 5.0% from the January 15th total of 17,270,000 shares. Based on an average trading volume of 1,900,000 shares, the short-interest ratio is presently 8.6 days. Approximately 12.2% of the shares of the company are short sold. View AVEO Pharmaceuticals' Current Options Chain.

Some companies that are related to AVEO Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other AVEO Pharmaceuticals investors own include Exelixis (EXEL), Synergy Pharmaceuticals (SGYP), Advanced Micro Devices (AMD), Micron Technology (MU), Novavax (NVAX), Alibaba Group (BABA), Canopy Growth (CGC), Amarin (AMRN), Bellicum Pharmaceuticals (BLCM) and Opko Health (OPK).

AVEO Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Jacobs Levy Equity Management Inc. (0.90%), Marshall Wace LLP (0.18%), Virtu Financial LLC (0.14%) and Goldman Sachs Group Inc. (0.03%). Company insiders that own AVEO Pharmaceuticals stock include Anthony B Evnin, Equity Opportunities Fu Growth, Equity Opportunities Iv Growth, Michael P Bailey, Peter J Barris, Peter W Sonsini and Ravi Viswanathan. View Institutional Ownership Trends for AVEO Pharmaceuticals.

AVEO stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc.. View Insider Buying and Selling for AVEO Pharmaceuticals.

AVEO stock was bought by a variety of institutional investors in the last quarter, including Jacobs Levy Equity Management Inc., Marshall Wace LLP and Virtu Financial LLC. Company insiders that have bought AVEO Pharmaceuticals stock in the last two years include Anthony B Evnin, Equity Opportunities Fu Growth, Equity Opportunities Iv Growth, Michael P Bailey, Peter J Barris, Peter W Sonsini and Ravi Viswanathan. View Insider Buying and Selling for AVEO Pharmaceuticals.

Shares of AVEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AVEO stock can currently be purchased for approximately $0.56.

AVEO Pharmaceuticals has a market capitalization of $89.88 million and generates $5.41 million in revenue each year. The biopharmaceutical company earns $-5,330,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis. AVEO Pharmaceuticals employs 17 workers across the globe.View Additional Information About AVEO Pharmaceuticals.

The official website for AVEO Pharmaceuticals is http://www.aveooncology.com/.

AVEO Pharmaceuticals' mailing address is ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-588-1960 or via email at [email protected]